Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
Cytokine
; 143: 155544, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1188449
ABSTRACT
The overproduction of proinflammatory cytokines, resulting in what has been described as a cytokine storm or cytokine release syndrome (CRS), may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19) and is also a crucial cause of death from COVID-19. With the purpose of finding effective and low-toxicity drugs to mitigate CRS, IL-1 blockade agents, which are one of the safest ways to stop this overwhelming innate immune response, are already available in several preliminary reports or are under observational trials and may offer an important treatment option in hyperinflammatory COVID-19. In this review, we described the key information in both case reports and clinical studies on the potential beneficial features of IL-1 inhibitors in COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Receptors, Interleukin-1
/
Interleukin 1 Receptor Antagonist Protein
/
Receptors, Interleukin-1 Type I
/
Cytokine Release Syndrome
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Cytokine
Journal subject:
Allergy and Immunology
Year:
2021
Document Type:
Article
Affiliation country:
J.cyto.2021.155544
Similar
MEDLINE
...
LILACS
LIS